helicobacter pylori
Conditions
Interventions
Polaprezinc group:polyprezinc quadruple therapy
Bismuth group:bismuth quadruple therapy
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18-70 years, no gender limit; 2. Had not received Hp eradication therapy before; 3. Positive Hp was diagnosed by C13/C14 urea breath test and rapid urease test; 4. Patients denied penicillin allergy history; 5. Patients were informed and consented to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Four weeks before treatment, antibiotics, bismuth agent, zinc agent (including health products containing zinc), Chinese traditional medicine with antibacterial effect (Huaweikang capsules, Banxia Xiexin Decoction, or traditional Chinese medicine prescriptions with rhubarb, coptis and scutellaria scutellaria as the main components, etc.) and probiotics were used; 2. PPI application history 2 weeks before treatment; 3. Complicated with serious systemic diseases, alcoholism and other serious diseases; 4. Mental illness, severe neurosis, unable to cooperate with this experiment; 5. Allergic to the drug in this study or penicillin in the past; 6. Pregnant or lactating patients; 7. The patient has participated in a clinical study involving investigational drug intervention within the past 30 days; 8. Patients with any other factors deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Countries
China
Contacts
Public ContactLi Jingnan
Peking Union Medical College Hospital
Outcome results
None listed